Anti-Parvovirus
Parvovirus B19 is the causative organism of fifth disease (erythema infectiosum). Differentiation between a fresh infection with Parvovirus B19 and exposure that occurred some time ago is of great importance for pregnant patients, since an intrauterine infection can cause severe foetal anaemia.
Approximately ten days after infection IgM antibodies are produced. IgG antibodies appear shortly after the formation of IgM or even simultaneously. In the acute phase of the infection IgG and IgM antibodies bind to linear epitopes of the entire structural protein or to conformational epitopes of the virus capsid. In many cases IgG antibodies preferably directed against conformational epitopes remain after decline of the initial IgM and IgG response, they usually persist for life.
Anti-Parvovirus B19 IgG
Alegria® Anti-Parvovirus B19 IgG is an ELISA-based, automated, in-vitro test system for the quantitative determination of IgG antibodies against Parvovirus B19 in human serum or plasma.
Anti-Parvovirus B19 IgG (ORG 912G) specifically detects IgG antibodies against the virus capsid protein VP2. The correct tertiary structure of the antigen is required for the sensitive detection of IgG antibodies from past infections. The Anti-Parvovirus B19 IgG ELISA uses recombinant VP2 as antigen, which is bound to the microtitre plate in the form of virus-like particles. These form three-dimensional structures that look like viral capsids, presenting the relevant antigen in the correct conformation. This results in very highly sensitive IgG detection in the acute phase of the infection as well as in those that occurred in the past.
Specifications
| Product Number |
ORG 912G |
| Tests | 24 Alegria® strips |
| Calibration | WHO (NIBSC code 01/602) |
| Calculation | quantitative |
| Range | 0 - 50 IU/ml |
| Cut-off | 3 IU/ml |
| Coating |
VP2 virus-like particles (recombinant) |
|
|
|
Instruction for Use Revision 3. Earlier versions and additional languages can be found in the document archive.
|
Anti-Parvovirus B19 IgM Abs.
The Alegria® Anti-Parvovirus B19 IgM Abs. test is an ELISA-based, automated, in-vitro test system for the quantitative determination of IgM antibodies against Parvovirus B19 in human serum or plasma.
Anti-Parvovirus B19 IgM Abs. (ORG 912MX) specifically detects IgM antibodies against the viral capsid protein VP2. This allows for specific detection of IgM antibodies in the acute phase just after initial exposure to the virus, indicating a fresh infection.
The Anti-Parvovirus IgM Abs. (ORG 912MX) test is equipped with the ORGENTEC rheumatoid factor absorbent. This reagent absorbs any rheumatoid factors that may be present during sample processing in the Alegria® instrument, making separate preparation of the serum sample unnecessary.
Specifications
| Product Number |
ORG 912MX |
| Tests | 24 Alegria® strips |
| Calibration | internal |
| Calculation | quantitative |
| Range | 0 - 200 U/ml |
| Cut-off | 25 U/ml |
| Coating |
VP2 virus-like particles (recombinant) |
|
|
|
Instruction for Use Revision 6. Earlier versions and additional languages can be found in the document archive.
|
